BB's Stock Haven

[wireshark43]

NEWS -- Aytu Featured on NBC and Fox News (VIDEO): "Denver officers, firefighters will be among first in US to get rapid COVID-19 tests"; "Denver scores 2,700 COVID-19 rapid tests for first responders"

100,000 COVID-19 Rapid Tests Ready to Ship Across the Country with 500,000 More on the Way

ENGLEWOOD, CO / ACCESSWIRE / April 6, 2020 / Aytu BioScience, Inc. (AYTU), (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs was featured on a FOX segment titled: "Denver officers, firefighters will be among first in US to get rapid COVID-19 tests," reported on by affiliated television station in Denver, Colorado, KDVR; and on an NBC segment titled "Denver scores 2,700 COVID-19 rapid tests for first responders - Aytu Bioscience in Englewood has 100,000 tests ready to ship across the country with 500,000 more on the way," reported on by affiliated television station in Denver, Colorado, 9News.

To view the video segments in their entirety and to read the articles, please visit the links below:

FOX (VIDEO & Article)
https://kdvr.com/news/coronavirus/denver-officers-firefighters-will-be-among-first-in-us-to-get-rapid-covid-19-tests/

NBC (VIDEO & Article)
https://www.9news.com/article/news/denver-scores-2700-covid-19-rapid-tests-for-first-responders/73-29d83678-b8a3-4ec6-97ee-0829add97134

The COVID-19 IgG/IgM Rapid Test is a serology test used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 126 patient clinical trial in China and is CE marked.

The Company believes that serology tests are a potentially powerful tool for identifying anyone who has been infected, whether they had symptoms or not. Antibodies to coronaviruses typically remain in humans for up to 90 days or more. The Company believes that serological testing is important in identifying the total number of people who have been infected with COVID-19. This type of testing could be particularly important for the immune surveillance of health care workers, first responders, government workers, and others whose infection risks could be heightened by working with COVID-19 infected individuals.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking.

Aytu recently acquired Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human® marketing and sales platform.

Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.